---
title: "09:14 ETPhanes Therapeutics to Present Three Clinical Posters at AACR 2026"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/279608985.md"
description: "Phanes Therapeutics, Inc. will present three clinical posters at the AACR 2026, showcasing their Phase 2 trial of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47. The presentations will cover pharmacokinetics, efficacy in reducing nausea, and resolving hematological toxicities. Spevatamig has received orphan drug and Fast Track designations for pancreatic cancer treatment. Phanes is advancing a portfolio of antibody therapeutics for solid tumors, including ongoing trials for spevatamig in the US and China."
datetime: "2026-03-18T13:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279608985.md)
  - [en](https://longbridge.com/en/news/279608985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279608985.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279608985.md) | [English](https://longbridge.com/en/news/279608985.md)


# 09:14 ETPhanes Therapeutics to Present Three Clinical Posters at AACR 2026

, /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present three posters from their ongoing Phase 2 clinical trial with spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47, at the American Association for Cancer Research (AACR) held on April 17-22 in San Diego, CA. All three posters will be presented under the Phase II and Phase III Clinical Trials Session. Details of each presentation are below:

**Title:** Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy

**Date/Time:** 4/20/2026 | 2:00-5:00 PM PST  
**Location:** Poster Section 52  
**Poster Board Number:** 8  
**Abstract Presentation Number:** CT144  
**First Author:** Anwaar Saeed, MD, University of Pittsburgh Medical Center

**Title:** Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody

**Date/Time:** 4/20/2026 | 2:00-5:00 PM PST  
**Location:** Poster Section 52  
**Poster Board Number:** 6  
**Abstract Presentation Number:** CT142  
**First Author:** Michael Overman, MD, University of Texas MD Anderson Cancer Center

**Title:** Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study

**Date/Time:** 4/20/2026 | 2:00-5:00 PM PST  
**Location:** Poster Section 52  
**Poster Board Number:** 7  
**Abstract Presentation Number:** CT143  
**First Author:** Harshabad Singh, MD, Mass General Brigham

**ABOUT SPEVATAMIG  
**Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.

The US multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced gastric, gastroesophageal junction, pancreatic ductal or biliary tract adenocarcinomas. The Phase 2 study of spevatamig has begun in China (CTR20241655).

**ABOUT PHANES THERAPEUTICS  
**Phanes Therapeutics is a San Diego–based, clinical-stage immuno-oncology company advancing a wholly owned portfolio of differentiated antibody therapeutics for solid tumors. Phanes is conducting Phase 1/2 trials across three in-house developed programs. The most advanced asset spevatamig, a first-in-class CLDN18.2 × CD47 bispecific antibody developed using Phanes' proprietary technology platforms, has demonstrated positive Phase 2 results in first-line metastatic pancreatic ductal adenocarcinoma. Peluntamig, a DLL3 × CD47 bispecific, is in clinical development for small cell lung cancer and neuroendocrine carcinomas. Both programs have received FDA Fast Track and Orphan Drug designations. Mavrostobart, a best-in-class anti-CD73 monoclonal antibody, further expands Phanes' differentiated immuno-oncology pipeline.

CONTACT: \[email protected\]

SOURCE Phanes Therapeutics, Inc.

## 相關資訊與研究

- [12:39 ETThe Mark Foundation for Cancer Research and Samuel Waxman Cancer Research Foundation Merger Finalized](https://longbridge.com/zh-HK/news/281402550.md)
- [Kennedy sidelining of US advisory panel delays updates to cancer screening guidelines](https://longbridge.com/zh-HK/news/281503258.md)
- [BrYet US, Inc. to Present ML-016 Preclinical Efficacy Data at AACR 2026](https://longbridge.com/zh-HK/news/281647557.md)
- [Viking Mergers & Acquisitions Sponsors Rising Leaders Bestie Brunch Benefiting Children's Cancer Center](https://longbridge.com/zh-HK/news/281525633.md)
- [05:55 ETNew Paper in Translational Insights Presents a Unifying Theory for How the Immune System Recognizes Cancer](https://longbridge.com/zh-HK/news/281502039.md)